- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03076099
Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization
6 de março de 2017 atualizado por: Nan Jiang
Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization
Aim of this trial is to study the effect of Dexmedetomidine on post-operative blood pressure in patients undergoing brain arteriovenous malformation embolization.
The patients were randomized allocated to either Dexmedetomidine group or Control group.
Patients in Dexmedetomidine group will receive intravenous Dexmedetomidine while the control group will receive normal saline.
Post-operative anti-hypertensive drug, Visual analogue score,post-operative analgesics consumption, Quality of Recovery score, Ramsay score, and adverse events were recorded.
Visão geral do estudo
Status
Desconhecido
Condições
Intervenção / Tratamento
Descrição detalhada
Aim of this trial is to study the effect of Dexmedetomidine on post-operative blood pressure in patients undergoing brain arteriovenous malformation embolization.
The patients were randomized allocated to either Dexmedetomidine group or Control group according to a random number.
Patients in Dexmedetomidine group will receive intravenous Dexmedetomidine while the control group will receive normal saline.
Post-operative anti-hypertensive drug, Visual analogue score,post-operative analgesics consumption, Quality of Recovery score-15 items, Ramsay score, and adverse events were recorded.
Tipo de estudo
Intervencional
Inscrição (Antecipado)
30
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recrutamento
- the First Affiliated Hospital of Sun Yetsen University
-
Contato:
- Yi Liu, Master
- Número de telefone: +86 13632391455
- E-mail: liuyisysu@126.com
-
Contato:
- Nan Jiang, professor
- Número de telefone: +86 20 28823350
- E-mail: NJiang_sysu@126.com
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 65 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- patients undergoing brain arteriovenous malformation embolization in the fist affiliated hospital, Sun Yat-sen University, aged 18-65 years, available to chat with,and the tracheal tube was extubated after surgery immediately.
Exclusion Criteria:
- abuse anesthetic analgesics and sedative drugs, or allergic to Dexmedetomidine or other anesthetics, hypotension or bradycardia before surgery, severe pulmonary disease with saturation of pulse oximetry less than 90% before surgery, or patients refused to attend in this study.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Dexmedetomidine
Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
|
1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
Outros nomes:
|
|
Comparador de Placebo: Control group
Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
|
equal volume of normal saline was administered intravenously constantly after tracheal extubation.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
urapidil consumption
Prazo: the end of the 6th hour after tracheal extubation
|
urapidil consumption was recorded by nurses every hour
|
the end of the 6th hour after tracheal extubation
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
urapidil consumption on POD1
Prazo: the total consumption of urapidil on post-operative day 1.
|
urapidil consumption was recorded by nurses every hour
|
the total consumption of urapidil on post-operative day 1.
|
|
urapidil consumption on POD2
Prazo: the total consumption of urapidil on post-operative day 2.
|
urapidil consumption was recorded by nurses every hour
|
the total consumption of urapidil on post-operative day 2.
|
|
Visual Analogue score
Prazo: the end of the 6th hour after tracheal extubation
|
visual analogue score was measured by visual analogue scale
|
the end of the 6th hour after tracheal extubation
|
|
Visual Analogue score at 24th hour
Prazo: the end of the 24th hour after tracheal extubation
|
visual analogue score was measured by visual analogue scale
|
the end of the 24th hour after tracheal extubation
|
|
Visual Analogue score at 48th hour
Prazo: the end of the 48th hour after tracheal extubation
|
visual analogue score was measured by visual analogue scale
|
the end of the 48th hour after tracheal extubation
|
|
Quality of Recovery Score
Prazo: the end of the 6th hour after tracheal extubation
|
Quality of Recovery Score was measured by a 15-item quality of recovery scale
|
the end of the 6th hour after tracheal extubation
|
|
Quality of Recovery Score at 24th hour
Prazo: the end of the 24th hour after tracheal extubation
|
Quality of Recovery Score was measured by a 15-item quality of recovery scale
|
the end of the 24th hour after tracheal extubation
|
|
Quality of Recovery Score at 48th hour
Prazo: the end of the 48th hour after tracheal extubation
|
Quality of Recovery Score was measured by a 15-item quality of recovery scale
|
the end of the 48th hour after tracheal extubation
|
|
Analgesics consumption
Prazo: the end of the 6th hour after tracheal extubation
|
Analgesics consumption was recorded by nurse every hour
|
the end of the 6th hour after tracheal extubation
|
|
Analgesics consumption on POD1
Prazo: the total consumption of urapidil on post-operative day 1.
|
Analgesics consumption was recorded by nurse every hour
|
the total consumption of urapidil on post-operative day 1.
|
|
Analgesics consumption on POD2
Prazo: the total consumption of urapidil on post-operative day 2.
|
Analgesics consumption was recorded by nurse every hour
|
the total consumption of urapidil on post-operative day 2.
|
|
Bradycardia
Prazo: the end of the 6th hour after tracheal extubation
|
a heart rate of lower than 50 beats per minute was identified as bradycardia, frequency of bradycardia was recorded by nurse
|
the end of the 6th hour after tracheal extubation
|
|
Bradycardia at 24th hour
Prazo: the end of the 24th hour after tracheal extubation
|
a heart rate of lower than 50 beats per minute was identified as bradycardia, frequency of bradycardia was recorded by nurse
|
the end of the 24th hour after tracheal extubation
|
|
Bradycardia at 48th hour
Prazo: the end of the 48th hour after tracheal extubation
|
a heart rate of lower than 50 beats per minute was identified as bradycardia, frequency of bradycardia was recorded by nurse
|
the end of the 48th hour after tracheal extubation
|
|
PONV
Prazo: the end of the 6th hour after tracheal extubation
|
post-operative nausea and vomiting (PONV) was recorded by nurse
|
the end of the 6th hour after tracheal extubation
|
|
PONV at 24th hour
Prazo: the end of the 24th hour after tracheal extubation
|
post-operative nausea and vomiting (PONV) was recorded by nurse
|
the end of the 24th hour after tracheal extubation
|
|
PONV at 48th hour
Prazo: the end of the 48th hour after tracheal extubation
|
post-operative nausea and vomiting (PONV) was recorded by nurse
|
the end of the 48th hour after tracheal extubation
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de janeiro de 2016
Conclusão Primária (Antecipado)
31 de dezembro de 2017
Conclusão do estudo (Antecipado)
31 de dezembro de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
6 de março de 2017
Enviado pela primeira vez que atendeu aos critérios de CQ
6 de março de 2017
Primeira postagem (Real)
9 de março de 2017
Atualizações de registro de estudo
Última Atualização Postada (Real)
9 de março de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
6 de março de 2017
Última verificação
1 de março de 2017
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças cardiovasculares
- Doenças Vasculares
- Anormalidades cardiovasculares
- Malformações Vasculares
- Anomalias congénitas
- Malformações Arteriovenosas
- Efeitos Fisiológicos das Drogas
- Agentes Adrenérgicos
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Depressores do Sistema Nervoso Central
- Agentes do Sistema Nervoso Periférico
- Analgésicos
- Agentes do Sistema Sensorial
- Analgésicos, Não Narcóticos
- Agonistas de Receptores Alfa-2 Adrenérgicos
- Alfa-Agonistas Adrenérgicos
- Agonistas Adrenérgicos
- Hipnóticos e Sedativos
- Dexmedetomidina
Outros números de identificação do estudo
- NJiang2016-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
the IPD will not be shared with others, since following investigations based on this trial is about to start.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .